The Anatolian Lens monitored the procedures for the third test of the Russian vaccine against the emerging corona virus, on volunteers.
The Russian National Epidemiology and Microbiology Research Center (Gamali) conducted the third test of the "Sputnik V" vaccine against Corona on volunteers yesterday, Thursday.
The Anadolu Agency team took clips and pictures of a vaccine test on volunteers in the capital, Moscow.
On August 11, the Russian Ministry of Health registered the vaccine against the Corona virus, and called it "Sputnik V". Specialists in the "Gamali" center worked on producing the vaccine with the support of the local direct investment fund.
And the ministry announced the start of distributing the first batch of the vaccine to Russian provinces.
According to the official website of the vaccine, "Sputnik V" is based on vectors of the adenovirus, and "vectors" are carriers that can deliver the genetic material from another virus to the cell, and the genetic material for the adenovirus that causes the infection is removed, while a gene that carries a code for a protein from Another virus, and in the current state of the Coronavirus, this new element is safe for the body, but it helps the immune system in responding and producing antibodies that protect the body from infection.
Russian researchers extracted part of the genetic material for the emerging corona virus "SARS Cove 2" (Anatolia)
The site adds that after the start of the pandemic, Russian researchers extracted part of the genetic material for the emerging corona virus "SARS Cove 2", which encodes data about the structure of the "S" protein (the protein that forms the "crown" of the virus and is responsible for its association with human cells), and implanted it within a vector known to They had adenoviruses in order to deliver it to the human cell, and thus the world's first vaccine against the Corona virus was found.
In order to provide long-term immunity, Russian scientists proposed using two different types of adenovirus-based vectors in the first and second vaccinations, which would enhance the effectiveness of the vaccine.
Although the vaccine is usually developed, tested and then manufactured commercially, procedures for developing a vaccine are being accelerated all over the world in unprecedented ways, and countries and large institutions are working to raise funds to develop the vaccine against Corona at the international level.
This allows companies to start commercial manufacturing of the vaccine at the same time that they are developing and testing it, although under normal circumstances this is done in two separate phases.
Many countries that have provided advance financing and signed priority contracts with developing companies will have priority in acquiring the Coronavirus vaccine.